Details for Patent: 9,388,159

Which drugs does patent 9,388,159 protect, and when does it expire?

Patent 9,388,159 protects ERLEADA and is included in one NDA.

This patent has eighty-two patent family members in nineteen countries.

Summary for Patent: 9,388,159

Title:	Substituted diazaspiroalkanes as androgen receptor modulators
Abstract:	This invention provides for compounds of the Formula II: ##STR00001## wherein A, B, Het, R.sub.1, R.sub.2 and R.sub.3 are as described herein. These compounds are androgen receptor modulators useful for the treatment of androgen receptor-associated conditions.
Inventor(s):	Jung; Michael E. (Los Angeles, CA), Sawyers; Charles L. (New York, NY), Ouk; Samedy (Los Angeles, CA), Tran; Chris (New York, NY), Wongvipat; John (New York, NY)
Assignee:	THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (Oakland, CA)
Application Number:	14/318,234
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 9,388,159
Patent Claim Types: see list of patent claims	Composition; Formulation; Compound; Delivery; Dosage form;

Drugs Protected by US Patent 9,388,159

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Janssen Biotech	ERLEADA	apalutamide	TABLET;ORAL	210951-001	Feb 14, 2018		RX	Yes	No			Y	Y
Janssen Biotech	ERLEADA	apalutamide	TABLET;ORAL	210951-002	Feb 17, 2023		RX	Yes	Yes			Y	Y

International Family Members for US Patent 9,388,159

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2007243651
Brazil	PI0709771
China	101454002
Cyprus	1114623
Cyprus	1117540
Cyprus	1117958